New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTBAYRY, ONXXBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
12:12 EDTBAYRYOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
08:37 EDTBAYRYOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
September 25, 2014
11:25 EDTBAYRYBayer said to not plan spin-off of Agrochem unit, Bloomberg reports
Subscribe for More Information
September 23, 2014
09:00 EDTBAYRYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
05:17 EDTBAYRYRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information
September 19, 2014
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
September 18, 2014
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
September 17, 2014
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use